Location of Repository

The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya

By Rachel Ochola, Charles Sande, Greg Fegan, P. D. (Paul D.) Scott, Graham Medley, Patricia Cane and D. James Nokes

Abstract

Background\ud Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection in infants. The rate of decay of RSV-specific maternal antibodies (RSV-matAb), the factors affecting cord blood levels, and the relationship between these levels and protection from infection are poorly defined.\ud Methods\ud A birth cohort (n = 635) in rural Kenya, was studied intensively to monitor infections and describe age-related serological characteristics. RSV specific IgG antibody (Ab) in serum was measured by the enzyme linked immunosorbent assay (ELISA) in cord blood, consecutive samples taken 3 monthly, and in paired acute and convalescent samples. A linear regression model was used to calculate the rate of RSV-matAb decline. The effect of risk factors on cord blood titres was investigated.\ud Results\ud The half-life of matAb in the Kenyan cohort was calculated to be 79 days (95% confidence limits (CL): 76–81 days). Ninety seven percent of infants were born with RSV-matAb. Infants who subsequently experienced an infection in early life had significantly lower cord titres of anti-RSV Ab in comparison to infants who did not have any incident infection in the first 6 months (P = 0.011). RSV infections were shown to have no effect on the rate of decay of RSV-matAb.\ud Conclusion\ud Maternal-specific RSV Ab decline rapidly following birth. However, we provide evidence of protection against severe disease by RSV-matAb during the first 6–7 months. This suggests that boosting maternal-specific Ab by RSV vaccination may be a useful strategy to consider

Topics: RA0421, RJ
Publisher: Public Library of Science
Year: 2009
OAI identifier: oai:wrap.warwick.ac.uk:2365

Suggested articles

Preview

Citations

  1. (1983). Antibodies to respiratory syncytial virus polypeptides and their significance in human infection. doi
  2. (2003). Antibody response after RSV infection in children younger than 1 year of age living in a rural area of Mozambique. doi
  3. (2004). Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus. doi
  4. (2001). Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. doi
  5. (2002). Epidemiology and clinical presentation of respiratory syncytial virus infection in a rural area of southern Mozambique. doi
  6. (2000). Estimation of incidence of respiratory syncytial virus infection in schoolchildren using salivary antibodies. doi
  7. (2000). Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. doi
  8. (2001). Half-life of human parainfluenza virus type 3 (hPIV3) maternal antibody and cumulative proportion of hPIV3 infection in young infants. doi
  9. (1981). Maternal antibody and respiratory syncytial virus infection in infancy. doi
  10. (1998). Maternal immunization against viral disease. doi
  11. (2002). Ministry of Finance and Planning. Analytical report on population projections. Vol VII. Central Bureau of Statistics
  12. (1979). Neonatal respiratory syncytial virus infection. doi
  13. (1998). Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. doi
  14. (2002). Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique. doi
  15. (1997). Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. doi
  16. (1996). Respiratory syncytial virus bronchiolitis: clinical aspects and epidemiology.
  17. (2004). Respiratory syncytial virus epidemiology in a birth cohort from Kilifi district, Kenya: infection during the first year of life. doi
  18. (2008). Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, doi
  19. (1970). Respiratory syncytial virus infection of the newborn. doi
  20. (1997). Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. doi
  21. (1986). Risk of primary infection and reinfection with respiratory syncytial virus.
  22. (1981). Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. doi
  23. (1976). Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. doi
  24. (2003). Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. doi
  25. (2009). Seasonal variation of maternally derived Respiratory Syncytial Virus antibodies and association with infant hospitalizations for Respiratory Syncytial Virus. doi
  26. (1986). Seasonal variations in maternal serum and mammary immunity to RS virus. doi
  27. (1998). Seroepidemiological study of respiratory syncytial virus in Sao Paulo state, doi
  28. (2004). The progression of maternal RSV antibodies in the offspring. doi
  29. (1979). Transfer of measles, mumps, and rubella antibodies from mother to infant. Its effect on measles, mumps, and rubella immunization. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.